Bulletin from Gunnebo AB’s Annual General Meeting 2014

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 10, 2014 at 12:00 PM

Gunnebo AB held its Annual General Meeting for 2014 in Gothenburg on 10 April. Adoption of the profit and loss statement and balance sheet The profit and loss statements and the balance sheets of the parent company and the Group for the financial year 2013 were approved. Dividend In accordance with the proposal of the Board and the President, it was decided on a dividend to the shareholders of SEK 1.00 per share (previous year SEK 1.00) and that Tuesday, April 15, 2014, shall be the record date for receipt of the dividend. Election of the Board of Directors Tore Bertilsson, Göran Bille, Charlotte Brogren, Bo Dankis, Mikael Jönsson and Martin Svalstedt were re-elected as members of the Board of Directors. Martin Svalstedt was re-elected as Chairman of the Board. Board fees The AGM decided on a total fee to the Board of Directors for 2014 amounting to SEK 1,750,000, to be divided with SEK 500,000 to the Chairman of the Board (including remuneration for committee work) and with SEK 250,000 to each of the other Board members elected by the shareholders, and a special fee for committee work amounting to SEK 50 000 for the respective chairman of the Audit Committee and the Remuneration Committee and SEK 30 000 each to other committee members. Nomination Committee The AGM approved the proposal presented regarding the Nomination Committee and its tasks. Election of the Auditor The AGM re-elected the registered auditing company Deloitte AB for the period until the end of the Annual General Meeting of the Shareholders 2015. Principles for remuneration to senior executives The AGM approved the Board’s proposal regarding principles for remuneration to senior executives. Comments from President’s address to the AGM Gunnebo’s President and CEO Per Borgvall started his address to the Annual General Meeting with a short description of the Group’s business and customers. This was followed by a summary of the 2013 financial year and sharing of focus areas for Gunnebo in 2014: "Our business has continued to develop in the right strategic direction during 2013. We have seen continued strong growth on markets in the Asia-Pacific and Americas regions, and in Europe we have noticed the first signs of stabilisation. "For Gunnebo, 2014 will mean continuing down the road to delivering improved financial results. We will continue to move our point of gravity geographically as well as in terms of how we allocate our resources and move up the value chain. We will also continue to reduce costs in Europe in order to improve our gross margins and further strengthen our cash flow. "Along with a clear strategy, a strong financial position and motivated employees, this will help us continue to create value for our shareholders, customers and business partners in the future.” GUNNEBO AB (publ) Group Finance Gunnebo discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 17:46 CET on April 10, 2014. For further information, please contact: Per Borgvall, President & CEO, tel. +46 10 2095 000, Christian Johansson, CFO tel. +46 10 2095 000, or Karin Wallström, Marketing & Communication Director, tel. +46 10 2095 026, e -mail: karin.wallstrom@gunnebo.com www.gunnebogroup.com The Gunnebo Security Group is a global leader in security products, services and solutions with an offering covering cash handling, safes and vaults, entrance security and electronic security for banks, retail, CIT, mass transit, public & commercial buildings and industrial & high-risk sites. The Group has an annual turnover of €610 million, employs 5,600 people and has sales companies in 33 countries across Europe, Middle East & Africa, Asia -Pacific and the Americas as well as Channel Partners on over 100 additional markets. We make your world safer.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...